Observation of c.260A > G mutation in superoxide dismutase 1 that causes p.Asn86Ser in Iranian amyotrophic lateral sclerosis patient and absence of genotype/phenotype correlation

  • Marzieh Khani Department of Biology, School of Science, University of Tehran, Tehran, Iran
  • Afagh Alavi Department of Biology, School of Science, University of Tehran, Tehran, Iran
  • Shahriar Nafissi Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  • Elahe Elahi Mail Department of Biology AND Department of Biotechnology, School of Science, University of Tehran, Tehran, Iran
Keywords:
Amyotrophic Lateral Sclerosis, Genotype Phenotype Correlation, Mutation, p.Asn86Ser, Superoxide Dismutase 1

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disorder in European populations. ALS can be sporadic ALS (SALS) or familial ALS (FALS). Among 20 known ALS genes, mutations in C9orf72 and superoxide dismutase 1 (SOD1) are the most common genetic causes of the disease. Whereas C9orf72 mutations are more common in Western populations, the contribution of SOD1 to ALS in Iran is more than C9orf72. At present, a clear genotype/phenotype correlation for ALS has not been identified. We aimed to perform mutation screening of SOD1 in a newly identified Iranian FALS patient and to assess whether a genotype/phenotype correlation for the identified mutation exists.
Methods: The five exons of SOD1 and flanking intronic sequences of a FALS proband were screened for mutations by direct sequencing. The clinical features of the proband were assessed by a neuromuscular specialist (SN). The phenotypic presentations were compared to previously reported patients with the same mutation.
Results: Heterozygous c.260A > G mutation in SOD1 that causes Asn86Ser was identified in the proband. Age at onset was 34 years and site of the first presentation was in the lower extremities. Comparisons of clinical features of different ALS patients with the same mutation evidenced variable presentations.
Conclusion: The c.260A > G mutation in SOD1 that causes Asn86Ser appears to cause ALS with variable clinical presentations.

References

1.Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344(22): 1688-700.
2.Charcot JM. Deux cas d'atrophie musculaire progressive: avec lésions de la substance grise et des faisceaux antérolatéraux de la moelle épinière. Arch Physiol Neurol Pathol 1869; 2: 744-54. [In French].
3.Nelson LM. Epidemiology of ALS. Clin Neurosci 1995; 3(6): 327-31.
4.Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68(5): 326-37.
5.Rison RA, Beydoun SR. Amyotrophic lateral sclerosis-motor neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature. J Med Case Rep 2010; 4: 298.
6.Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet 2013; 83(5): 408-16.
7.Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 3.
8.Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6(1): 37-46.
9.Shirakawa K, Suzuki H, Ito M, Kono S, Uchiyama T, Ohashi T, et al. Novel compound heterozygous ALS2 mutations cause juvenile amyotrophic lateral sclerosis in Japan. Neurology 2009; 73(24): 2124-6.
10.Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keranen ML, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn- superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119 (Pt 4): 1153-72.
11.Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6(11): 994-1003.
12.Alavi A, Nafissi S, Rohani M, Zamani B, Sedighi B, Shamshiri H, et al. Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. Neurobiol Aging 2013; 34(5): 1516-8.
13.Sapp PC, Rosen DR, Hosler BA, Esteban J, McKenna-Yasek D, O'Regan JP, et al. Identification of three novel mutations in the gene for Cu/Zn superoxide dismutase in patients with familial amyotrophic lateral sclerosis. Neuromuscul Disord 1995; 5(5): 353-7.
14.Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122(6): 657-71.
15.Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7(11): 603-15.
16.Wroe R, Wai-Ling BA, Andersen PM, Powell JF, Al-Chalabi A. ALSOD: the Amyotrophic Lateral Sclerosis Online Database. Amyotroph Lateral Scler 2008; 9(4): 249-50.
17.Renton AE, Majounie E, Waite A, Simon- Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72(2): 257-68.
18.Shaw CE, Al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001; 1(1): 69-76.
19.DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72(2): 245-56.
20.Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11(4): 323-30.
21.Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33(10): 2527-6.
22.Tsai CP, Soong BW, Tu PH, Lin KP, Fuh JL, Tsai PC, et al. A hexanucleotide repeat expansion in C9ORF72 causes familial and sporadic ALS in Taiwan. Neurobiol Aging 2012; 33(9): 2232.
23. Alavi A, Nafissi S, Rohani M, Shahidi G, Zamani B, Shamshiri H, et al. Repeat expansion in C9ORF72 is not a major cause of amyotrophic lateral sclerosis among Iranian patients. Neurobiol Aging 2014; 35(1): 267.
24. Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 2011; 71(4): 281-8.
25. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362(6415): 59-62.
26. Radunovic A, Leigh PN. Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 1996; 61(6): 565-72.
27. Hayward C, Brock DJ, Minns RA, Swingler RJ. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet 1998; 35(2): 174.
28. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(5): 293-9.
29. Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998; 25(3): 192-6.
Published
2015-10-14
How to Cite
1.
Khani M, Alavi A, Nafissi S, Elahi E. Observation of c.260A > G mutation in superoxide dismutase 1 that causes p.Asn86Ser in Iranian amyotrophic lateral sclerosis patient and absence of genotype/phenotype correlation. Curr J Neurol. 14(3):152-157.
Section
Special Articles